Insights

Pricing & Compliance Valeant has faced historical scrutiny over accounting practices and pricing strategies, indicating a potential need for robust compliance, pricing analytics, and governance solutions to mitigate risk and restore trust with regulators and payers.

Strategic Acquisitions The company has engaged in significant M&A activity including acquisitions like Bausch + Lomb and AcneFree, suggesting opportunities in integration services, ERP optimization, and post-merger diligence to accelerate synergies.

Product Portfolio Valeant’s portfolio includes launches such as Addyi post-acquisition, highlighting a path for commercial enablement services, market access strategy, and specialty launch capabilities to support new and existing products.

Technology Stack The firm utilizes enterprise systems including SAP, Salesforce, SharePoint, and DNN, presenting openings for CRM optimization, data integration, and digital workplace enhancements to improve efficiency and decision-making.

Growth Profile With mid-market revenue in the several hundred million range and a social- and topic-driven growth narrative, Valeant represents a target for scalable managed services, cost optimization programs, and strategic outsourcing to support expansion and profitability.

Similar companies to VALEANT

VALEANT Tech Stack

VALEANT uses 8 technology products and services including DNN, Microsoft SharePoint, Salesforce, and more. Explore VALEANT's tech stack below.

  • DNN
    Content Management System
  • Content Management System
  • Customer Relationship Management
  • Customer Relationship Management
  • jQuery UI
    Javascript Libraries
  • Microsoft
    Miscellaneous
  • Microsoft Word
    Office Suites
  • Team Collaboration

Media & News

VALEANT's Email Address Formats

VALEANT uses at least 3 email formats:
VALEANT Email FormatsExamplePercentage
First.Last@valeant.comJohn.Doe@valeant.com
95%
FLast@valeant.comJDoe@valeant.com
4%
First.MiddleLast@valeant.comJohn.MichaelDoe@valeant.com
1%

Frequently Asked Questions

What is VALEANT's stock symbol?

Minus sign iconPlus sign icon
VALEANT is a publicly traded company; the company's stock symbol is VRX1.

What is VALEANT's official website and social media links?

Minus sign iconPlus sign icon
VALEANT's official website is valeant.com and has social profiles on LinkedIn.

How much revenue does VALEANT generate?

Minus sign iconPlus sign icon
As of August 2026, VALEANT's annual revenue is estimated to be $250M - $500M.

What is VALEANT's NAICS code?

Minus sign iconPlus sign icon
VALEANT's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does VALEANT have currently?

Minus sign iconPlus sign icon
As of August 2026, VALEANT has approximately 113 employees across 5 continents, including North America, Europe and Asia. Key team members include Vp Business Development: M. O., Head Of Accounting And Finance: I. Y. and Quality Compliance Director Emea: J. P. Explore VALEANT's employee directory with LeadIQ.

What industry does VALEANT belong to?

Minus sign iconPlus sign icon
VALEANT operates in the Pharmaceutical Manufacturing industry.

What technology does VALEANT use?

Minus sign iconPlus sign icon
VALEANT's tech stack includes DNN, Microsoft SharePoint, Salesforce, SAP, jQuery UI, Microsoft, Microsoft Word and Microsoft Teams.

What is VALEANT's email format?

Minus sign iconPlus sign icon
VALEANT's email format typically follows the pattern of First.Last@valeant.com. Find more VALEANT email formats with LeadIQ.
VALEANT logo

VALEANT

Pharmaceutical Manufacturing51-200 Employees

Valeant Pharmaceuticals International, Inc. operates as a diversified, decentralized pharmaceutical company that aims to deliver consistent performance for its stakeholders. Its stated values provide direction and support in meeting challenges through teamwork and a competitive spirit. The company is part of the pharmaceutical manufacturing industry and is based in Canada, with a mid-sized workforce. This structure reflects a focus on stakeholder engagement and sustained performance.

In 2022, Valeant launched flibanserin (Addyi) in the U.S. market following its acquisition of Sprout Pharmaceuticals.

Section iconCompany Overview

Stock Symbol
VRX1
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
51-200

Section iconFunding & Financials

  • $250M - $500M

    VALEANT's revenue is estimated to be in the range of $250M - $500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.